Angiogenesis in acute and chronic leukemias.
Angiogenesis plays a key role in the growth of solid tumors. More recently, accumulating evidence has linked angiogenesis to the pathophysiology of leukemias. Different investigators have shown evidence of increased angiogenesis in the bone marrows of patients with acute and chronic leukemias. Elevated levels of angiogenic factors have also been reported in leukemic patients. A potential role for VEGF as an autocrine growth factor in AML has been suggested. Studies on the role of angiogenesis and VEGF as prognostic factors in leukemia require confirmation. The role of angiogenesis inhibitors in the treatment of leukemia is currently under investigation.
Dickson
D J
DJ
Department of Medicine, University of Utah and SLC VA Medical Centers, Salt Lake City 84148, USA.
Shami
P J
PJ
D000208:Acute Disease; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000818:Animals; D001853:Bone Marrow / Q000098:blood supply / Q000473:pathology; D002908:Chronic Disease; D016228:Endothelial Growth Factors / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000502:physiology; D006133:Growth Substances / Q000378:metabolism / Q000502:physiology; D006801:Humans; D007938:Leukemia / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology*; D008222:Lymphokines / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000502:physiology; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology*; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D020533:Angiogenesis Inhibitors; D016228:Endothelial Growth Factors; D006133:Growth Substances; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors